Skip to main content

Unable to load price data. Sorry.


Synta Pharmaceuticals Corp. (NASDAQ:SNTA.DL)

CAPS Rating: No stars

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:SNTA.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

cibient (< 20)
Submitted February 04, 2010

Surge of insider buying inspires confidence. While this means nothing if the drug ultimately doesn't fly, or heavy dilution tramples existing shareholders, the company has a good balance sheet due to the recent capital raise.

zzlangerhans (98.81)
Submitted October 18, 2013

There's always that one last moment of hesitation before I hit the underperform button on an oncology stock in CAPS. Last chance to avoid making a fool of myself focusing on the corpse of a failed lead drug and completely unaware of the hot new… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about SNTA.DL.

No one has written a Pitch for SNTA.DL stock yet. Tell us why you think SNTA.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in SNTA.DL.

No players have picked SNTA.DL yet. Tell us why you think SNTA.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SNTA.DL.